Imugene forges development path of immunotherapies and cancer-killing virus

Imugene (ASX: IMU) managing director and chief executive officer Leslie Chong joins Small Caps to discuss the company’s development of its portfolio of immunotherapies, a cancer-killing virus (VAXINIA) and other emerging technologies.

Imugene is designing immunotherapies to assist a cancer patient’s immune system in fighting off its malignant cells, while VAXINIA is currently being evaluated in clinical trials.

Ms Chong says the company is incredibly eager to unlock the potential of its cancer-killing virus in patients across Australia and the United States where trials are being held.

Articles:
https://smallcaps.com.au/imugene-patent-pd1-vaxx-immunotherapy-progresses-cancer-killing-virus/

For more information on Imugene:
https://smallcaps.com.au/stocks/IMU/

-----------------------

Small Caps is Australia's #1 site for market news & information on ASX listed small cap companies.

-----------------------

WEBSITE
https://smallcaps.com.au/

PODCAST
https://smallcaps.com.au/podcast/

SOCIAL MEDIA
Facebook: https://www.facebook.com/SmallCapsASX
Twitter: https://twitter.com/SmallCapsASX
LinkedIn: https://www.linkedin.com/company/small-caps/

NEWSLETTER
https://smallcaps.com.au/subscribe/